• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cook Regentec spinout Sexton Biotechnologies raises $5m

September 24, 2019 By Sean Whooley

Cook Medical - updated logoCook Regentec spinout Sexton Biotechnologies said today that it raised $5 million for the cell and gene therapy bioproduction tools it’s developing.

The company is Cook’s first to pick up outside investment capital and spin out as an independent biotechnology company, according to a news release. Sexton is made up of a 17-person team from Cook Regentec that’s developed, incubated and commercialized products since 2015.

Investors providing Sexton with growth capital included BioLife Solutions, Casdin Capital, BioCrossroads and Cook Regentec.

Sexton said it will add the funds to its ongoing R&D and expand commercialization of its portfolio of container closure and media supplementation tools. It expects be fully independent of Cook Regentec Oct. 1. The company will remain in Cook Regentec’s Indianapolis facility through 2024.

“The opportunity to work closely with partners of such deep expertise in the cell and gene therapy industry will drive new focus to continue our growth,” Sexton president Sean Werner said in the news release. “We appreciate the support of Casdin Capital, a leading healthcare hedge fund focused on making multiple thematic investments in biotech ecosystems including the cell and gene therapy space. We’re also excited for the opportunity to work with BioLife Solutions to leverage their sales and marketing expertise and resources as we work to expand our customer base. This new round of investment gives us additional resources to further develop and support our unique products while strengthening our connections in the thriving Indiana life sciences sector through the relationship with BioCrossroads.”

Filed Under: Featured, Funding Roundup, Mergers & Acquisitions Tagged With: Cook Regentec, Sexton Biotechnologies

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS